FSCN1 and hepatocellular carcinoma: By specifically targeting and reducing the expression of TGF-β1, FSCN1 (Fascin Actin-Bundling Protein 1), and vimentin, EA exhibited the potential to obstruct pivotal processes closely associated with the development and progression of hepatocellular carcinoma (HCC).